Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience

Gowda, Raghavendra; Henk, J.M.; Mais, Kathleen L; Sykes, Andrew J; Swindell, Ric; Slevin, Nicholas J

doi:10.1016/s0167-8140(03)00059-8

Cited by 94 publications

(87 citation statements)

References 53 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,18,[22][23][24][25] In some reports these indicators reach 100%. 2,13,26 The publications on hypofractionated accelerated RT for larynx cancer present results in T1-T2 tumors while in our study T3 tumors were diagnosed in 8% of patients in the H group.…”

Section: Discussionmentioning

confidence: 99%

“…No difference in toxicity between standard and hypofractionated protocols was found in published reports of hypofractionated RT of the laryngeal cancer. 11,13,18,22,23,25 In majority of these reports a fraction dose of 2.25-2.5 Gy was used. The dose >3.0 Gy was linked to a higher complications rate, 13,34 but in a group of 200 patients reported by Gowda et al in which 3.12-3.28 Gy doses were used for 3 weeks up to a total of 50-52.5 Gy, early and late toxicity were low.…”

Section: Discussionmentioning

confidence: 99%

“…The dose >3.0 Gy was linked to a higher complications rate, 13,34 but in a group of 200 patients reported by Gowda et al in which 3.12-3.28 Gy doses were used for 3 weeks up to a total of 50-52.5 Gy, early and late toxicity were low. 22 Reduced use of radiotherapy resources depends mainly on reduced number of RT sessions. Accelerated regimes that deliver the same number of fractions as conventional RT, reduce the treatment duration, but utilize the same amount of RT equipment time.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls

Szutkowski

Kawecki

Jarząbski

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls

Szutkowski

Kawecki

Jarząbski

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…Accelerated hypofractionated irradiation of early‐stage larynx cancer originated in Europe, with early results mirroring those achieved with conventional therapy 5, 6. Despite conventional radiation techniques, there was no difference in cure rates when reducing radiation therapy from a 5‐week course down to 3 weeks 7.…”

Section: Introductionmentioning

confidence: 98%

“…Later, a British Institute of Radiology study showed equivalent survival rates and no significant differences in toxicity with either a 3‐week or 6‐week radiation course 6. More recently, the Royal Marsden Hospital treated 200 patients with T1 glottic cancer to a dose of 50–52.5 Gy in 16 daily fractions,5 matching outcomes from historical studies. Beyond patient convenience and cost‐saving advantages, hypofractionated radiation therapy may improve local control rates 8.…”

Section: Introductionmentioning

confidence: 99%

Online dosimetric evaluation of larynx SBRT: A pilot study to assess the necessity of adaptive replanning

Mao

Rozario

et al. 2016

J Applied Clin Med Phys

View full text Add to dashboard Cite

PurposeWe have initiated a multi‐institutional phase I trial of 5‐fraction stereotactic body radiotherapy (SBRT) for Stage III–IVa laryngeal cancer. We conducted this pilot dosimetric study to confirm potential utility of online adaptive replanning to preserve treatment quality.MethodsWe evaluated ten cases: five patients enrolled onto the current trial and five patients enrolled onto a separate phase I SBRT trial for early‐stage glottic larynx cancer. Baseline SBRT treatment plans were generated per protocol. Daily cone‐beam CT (CBCT) or diagnostic CT images were acquired prior to each treatment fraction. Simulation CT images and target volumes were deformably registered to daily volumetric images, the original SBRT plan was copied to the deformed images and contours, delivered dose distributions were re‐calculated on the deformed CT images. All of these were performed on a commercial treatment planning system. In‐house software was developed to propagate the delivered dose distribution back to reference CT images using the deformation information exported from the treatment planning system. Dosimetric differences were evaluated via dose‐volume histograms.ResultsWe could evaluate dose within 10 minutes in all cases. Prescribed coverage to gross tumor volume (GTV) and clinical target volume (CTV) was uniformly preserved; however, intended prescription dose coverage of planning treatment volume (PTV) was lost in 53% of daily treatments (mean: 93.9%, range: 83.9–97.9%). Maximum bystander point dose limits to arytenoids, parotids, and spinal cord remained respected in all cases, although variances in carotid artery doses were observed in a minority of cases.ConclusionsAlthough GTV and CTV SBRT dose coverage is preserved with in‐room three‐dimensional image guidance, PTV coverage can vary significantly from intended plans and dose to critical structures may exceed tolerances. Online adaptive treatment re‐planning is potentially necessary and clinically applicable to fully preserve treatment quality. Confirmatory trial accrual and analysis remains ongoing.

show abstract

The 3 Bs of cancer care amid the COVID‐19 pandemic crisis: “Be safe, be smart, be kind”—A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer

Kang

Wong

Sherman

et al. 2020

Cancer

View full text Add to dashboard Cite

Because of the national emergency triggered by the coronavirus disease 2019 (COVID‐19) pandemic, government‐mandated public health directives have drastically changed not only social norms but also the practice of oncologic medicine. Timely head and neck cancer (HNC) treatment must be prioritized, even during emergencies. Because severe acute respiratory syndrome coronavirus 2 predominantly resides in the sinonasal/oral/oropharyngeal tracts, nonessential mucosal procedures are restricted, and HNCs are being triaged toward nonsurgical treatments when cures are comparable. Consequently, radiation utilization will likely increase during this pandemic. Even in radiation oncology, standard in‐person and endoscopic evaluations are being restrained to limit exposure risks and preserve personal protective equipment for other frontline workers. The authors have implemented telemedicine and multidisciplinary conferences to continue to offer standard‐of‐care HNC treatments during this uniquely challenging time. Because of the lack of feasibility data on telemedicine for HNC, they report their early experience at a high‐volume cancer center at the domestic epicenter of the COVID‐19 crisis.

show abstract

Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience

Cited by 94 publications

References 53 publications

Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls

Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls

Online dosimetric evaluation of larynx SBRT: A pilot study to assess the necessity of adaptive replanning

The 3 Bs of cancer care amid the COVID‐19 pandemic crisis: “Be safe, be smart, be kind”—A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer

Contact Info

Product

Resources

About